Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.

Background

Limited data are available characterizing the impact of the SARS-CoV-2 pandemic on psoriasis care for patients in Germany.

Objective

To analyze patient perception and impact of the pandemic on well-being and psoriasis management of German patients with moderate-to-severe psoriasis or psoriasis arthritis under systemic therapies.

Methods

The CoronaBest registry captures events of SARS-CoV-2 infections and analyzes the impact of the pandemic on patients with psoriasis or psoriasis arthritis. In June 2020, and independently in February 2022, patients with psoriasis or psoriasis arthritis received a standardized questionnaire for current treatment, protective measures, well-being, and individual risks for COVID-19, among others.

Results

Included were 4,194 patients in 2020 (mean age of 47.7 years and 41.8% women) and 4,818 patients in 2022 (mean age of 56.4 and 42.9% women). Treatment discontinuations were observed in 2.7% and 1.7% of patients in 2020 and 2022, respectively. In the vast majority of the cases (>92%), no additional measures were taken concerning the management of psoriasis treatments in either 2020 or 2022. Those patients with changes reported most frequently: telephone calls instead of face-to-face visits (80.2%, in 2020 vs 40.5% in 2022) or more frequent controls (27.1%, 2020 vs 22.0%, 2022). A majority (66.7%, 2020, and 70.6%, 2022) did not perceive the virus as a considerable threat. The proportion of patients feeling well informed about COVID-19 by physicians increased from 42.6% in 2020 to 51.8% in 2022. About 81.1% of patients in 2020 and 67.5% in 2022 stated that their overall personal condition was not affected due to the pandemic. Physicians attributed no special risk of contracting SARS-CoV-2 in most of the patients.

Conclusion

A high rate of systemic treatment persistence and awareness of risks and protective measures indicate that health care for psoriasis largely followed current national and international recommendations during the COVID-19 pandemic.

Informations de copyright

© 2024 Valencia López et al.

Déclaration de conflit d'intérêts

B. Stephan received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events for AbbVie, UCB. D. Thaçi received grants or contracts from Novartis, Leo-Pharma; Consulting fees from AbbVie, Almirall, Lilly, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, UCB; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Amgen, Almirall, Lilly, Janssen, MSD, Medac, Novartis, Pfizer, UCB; participated on a Data Safety Monitoring Board or Advisory Board at AbbVie, Almirall, Celltrion, Lilly, Janssen, Novartis, Pfizer, UCB. U. Mrowietz has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Aditxt, Almirall, Amgen, Aristea, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Dr. Reddy’s, Eli Lilly, Foamix, Formycon, GlaxoSmithKline, Immunic, Janssen, LEO Pharma, Medac, MetrioPharm, Novartis, Phi-Stone, Pierre Fabre, Sanofi-Aventis, UCB Pharma, UNION Therapeutics. K. Reich received consulting fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen-Cilag, Kyowa Kirin, LEO, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, UCB; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Galderma, Janssen-Cilag, Kyowa Kirin, LEO, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, UCB; support for attending meetings and/or travel from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Galderma, Janssen-Cilag, Kyowa Kirin, LEO, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, UCB; participated on a Data Safety Monitoring Board or Advisory Board at AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Galderma, Janssen-Cilag, Kyowa Kirin, LEO, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, UCB and is co-founder of Moonlake Immunotherapeutics. P. Staubach received grants or contracts from Novartis; consulting fees from AbbVie, Almirall, Lilly, Janssen, Novartis, UCB, Leo, Amgen, BMS; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Amgen, Almirall, BMS; leo, Lilly, Janssen, Novartis, Pfizer, UCB. R. von Kiedrowski provides with his service company CMS3 GmbH consulting services, registry research, activities as an investigator in interventional and non-interventional studies, other services, and scientific lectures for the following companies: AbbVie, ALK Scherax, Almirall Hermal, Amgen, Beiersdorf Dermo Medical, Biofrontera, Biogen, BMS, Boehringer Ingelheim, Celgene, DermaPharm, Foamix, Gilead, Hexal, Janssen-Cilag, LEO Pharma, Lilly Pharma, Medac, Menlo, MSD, Mylan/Viatris, Novartis, Dr. R. Pfleger, Pfizer, Regeneron, Sanofi, Stallergens, Stiefel GSK, Tigercut and UCB. M. Augustin served as a consultant for or has been a paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Almirall, Amgen, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Eli Lilly, Galderma, Hexal, Janssen, LEO, Medac, MSD, Mylan B.V., Novartis, Pfizer, Sandoz, UCB and Viatris. The authors report no other conflicts of interest in this work.